HRP20140986T1 - Polimorfni oblik derivata 2-amino(nitroaril)tiazola - Google Patents
Polimorfni oblik derivata 2-amino(nitroaril)tiazola Download PDFInfo
- Publication number
- HRP20140986T1 HRP20140986T1 HRP20140986AT HRP20140986T HRP20140986T1 HR P20140986 T1 HRP20140986 T1 HR P20140986T1 HR P20140986A T HRP20140986A T HR P20140986AT HR P20140986 T HRP20140986 T HR P20140986T HR P20140986 T1 HRP20140986 T1 HR P20140986T1
- Authority
- HR
- Croatia
- Prior art keywords
- polymorphic form
- nitroaryl
- amino
- polymorph form
- thiazole derivative
- Prior art date
Links
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 title 1
- 125000004999 nitroaryl group Chemical group 0.000 title 1
- 150000007979 thiazole derivatives Chemical class 0.000 title 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims 2
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000002798 polar solvent Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Claims (5)
1. Polimorfni oblik spoja (IX), koji ostaje suh kod 80%-tne relativne vlažnosti i termodinamički je stabilan na temperaturama ispod 200 °C:
[image]
,
naznačen time što uzorak difrakcije rendgenskih zraka ima karakteristične signale, izražene u stupnjevima 2θ, na 7,269, 9,120, 11,038, 13,704, 14,481, 15,483, 15,870, 16,718, 17,087, 17,473, 18,224, 19,248, 19,441, 19,940, 20,441, 21,469, 21,750, 22,111, 23,319, 23,763, 24,120, 24,681, 25,754, 26,777, 28,975, 29,609, 30,073.
2. Polimorfni oblik spoja (IX), u skladu s patentnim zahtjevom 1, naznačen time što diferencijalna skenirajuća kalorimetrija (DSC) pokazuje pojedinačni najveći signal na 237,49 ± 0,3 °C.
3. Postupak dobivanja polimorfnog oblika u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačen time što se sastoji u obradi 4-(4-metilpiperazin-1-ilmetil)-N-[4-metil-3-(4-piridin-3-iltiazol-2-ilamino)fenil]benzamida metansulfonskom kiselinom, na temperaturi između 20 i 80 °C.
4. Postupak u skladu s patentnim zahtjevom 3, naznačen time što se reakcija provodi u polarnom otapalu.
5. Postupak u skladu s patentnim zahtjevom 3 ili patentnim zahtjevom 4, naznačen time što se reakcija provodi uz upotrebu 1,0 ekvivalenta metansulfonske kiseline.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88958707P | 2007-02-13 | 2007-02-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20140986T1 true HRP20140986T1 (hr) | 2014-11-21 |
Family
ID=39332208
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110709T HRP20110709T1 (hr) | 2007-02-13 | 2011-10-05 | Postupak sinteze spojeva 2-aminotioazola kao inhibitora kinaza |
HRP20140986AT HRP20140986T1 (hr) | 2007-02-13 | 2014-10-15 | Polimorfni oblik derivata 2-amino(nitroaril)tiazola |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110709T HRP20110709T1 (hr) | 2007-02-13 | 2011-10-05 | Postupak sinteze spojeva 2-aminotioazola kao inhibitora kinaza |
Country Status (23)
Country | Link |
---|---|
US (3) | US8153792B2 (hr) |
EP (2) | EP2366703B1 (hr) |
JP (2) | JP5568312B2 (hr) |
KR (1) | KR20090110851A (hr) |
CN (2) | CN101657446B (hr) |
AR (1) | AR065337A1 (hr) |
AT (1) | ATE515506T1 (hr) |
AU (1) | AU2008214679A1 (hr) |
BR (1) | BRPI0807626B1 (hr) |
CA (2) | CA2677586C (hr) |
ES (2) | ES2522169T3 (hr) |
HR (2) | HRP20110709T1 (hr) |
IL (1) | IL200320A0 (hr) |
MA (1) | MA31180B1 (hr) |
MX (1) | MX2009008665A (hr) |
NZ (1) | NZ578944A (hr) |
PL (2) | PL2118099T3 (hr) |
RU (2) | RU2456285C2 (hr) |
SI (2) | SI2118099T1 (hr) |
TN (1) | TN2009000342A1 (hr) |
TW (1) | TWI406862B (hr) |
WO (1) | WO2008098949A2 (hr) |
ZA (1) | ZA200905981B (hr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2294344T3 (es) | 2002-08-02 | 2008-04-01 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazoles y su utilizacion como inhibidores de c-kit. |
US8450302B2 (en) | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
US20120302577A1 (en) | 2010-01-28 | 2012-11-29 | Ab Science | Treatment of gist with masitinib |
AR080096A1 (es) | 2010-02-01 | 2012-03-14 | Ab Science | Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib |
AR080380A1 (es) | 2010-03-09 | 2012-04-04 | Ab Science | Tratamiento de la demencia tipo alzheimer con masitinib |
AR080933A1 (es) | 2010-04-20 | 2012-05-16 | Ab Science | Tratamiento de esclerosis multiple con masitinib |
TW201204719A (en) | 2010-06-02 | 2012-02-01 | Ab Science | Treatment of rheumatoid arthritis with masitinib |
WO2012059526A1 (en) | 2010-11-05 | 2012-05-10 | Ab Science | Treatment of mastocytosis with masitinib |
US10045978B2 (en) | 2010-11-05 | 2018-08-14 | Ab Science | Treatment of mastocytosis with masitinib |
WO2012104402A1 (en) * | 2011-02-04 | 2012-08-09 | Ab Science | Treatment of severe persitent asthma with masitinib |
WO2012136732A1 (en) | 2011-04-08 | 2012-10-11 | Ab Science | Treatment of multiple myeloma with masitinib |
SI2903616T1 (en) | 2012-10-04 | 2018-02-28 | Ab Science | The use of masitinib in combination with gemcitabine for the treatment of a subgroup of patients suffering from foot-and-mouth disease |
WO2015082496A1 (en) | 2013-12-02 | 2015-06-11 | Ab Science | Use of masitinib for treatment of colorectal cancer |
EP2886543A1 (en) | 2013-12-18 | 2015-06-24 | Sandoz Ag | Crystalline form of mastinib mesylate |
WO2015185958A1 (en) | 2014-06-02 | 2015-12-10 | Ab Science | Use of an inhibitor of kinase activity, particularly masitinib, for treatment of prostate cancer |
CN105585556A (zh) * | 2014-11-13 | 2016-05-18 | 连云港杰瑞药业有限公司 | 一种伊马替尼的合成方法 |
CN106794179A (zh) * | 2015-07-29 | 2017-05-31 | 苏州晶云药物科技有限公司 | 马赛替尼甲磺酸盐的新晶型及其制备方法 |
CA3000894A1 (en) | 2015-10-05 | 2017-04-13 | Ab Science | Treatment of severe systemic mastocytosis with masitinib |
EP3240538B1 (en) | 2016-03-25 | 2021-09-29 | AB Science | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation |
US10961235B2 (en) | 2017-03-31 | 2021-03-30 | Sandoz Ag | Crystalline form of masitinib |
US10696638B2 (en) | 2017-12-26 | 2020-06-30 | Industrial Technology Research Institute | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same |
EP4061371A1 (en) | 2019-11-22 | 2022-09-28 | AB Science | Masitinib for the treatment of sickle cell disease |
EP3831384A1 (en) | 2019-12-02 | 2021-06-09 | AB Science | Use of masitinib for the treatment of eosinophilic asthma |
CN115515590A (zh) | 2020-02-20 | 2022-12-23 | Ab科学有限公司 | 马赛替尼用于治疗多发性硬化患者亚群 |
CN115867278A (zh) | 2020-04-10 | 2023-03-28 | Ab科学有限公司 | 马赛替尼用于治疗2019冠状病毒病(covid-19)的用途 |
WO2022129410A1 (en) | 2020-12-16 | 2022-06-23 | Ab Science | Masitinib for the treatment of alzheimer's disease |
IL308088A (en) | 2021-05-17 | 2023-12-01 | Ab Science | Mestitinib for the treatment of castrate-resistant prostate cancer |
CN115850258A (zh) * | 2022-12-27 | 2023-03-28 | 东北林业大学 | 一种马赛替尼的合成方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3299087A (en) * | 1961-04-24 | 1967-01-17 | Geigy Chem Corp | Nu, nu'-bis-(thiazolyl)-phenylenediamines |
WO1998052937A2 (en) * | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | 4-aryl-3(5)-heteroaryl substituted pyrazoles as p38 kinase |
CO4940418A1 (es) * | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
YU22400A (sh) * | 1997-10-27 | 2003-08-29 | Agouron Pharmaceuticals Inc. | Supstituisana 4-amino-tiazol-2-i jedinjenja kao cdks inhibitori |
US6114365A (en) * | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
ATE309241T1 (de) * | 1999-09-10 | 2005-11-15 | Merck & Co Inc | Tyrosin kinase inhibitoren |
ATE376182T1 (de) | 2001-06-29 | 2007-11-15 | Ab Science | C-kit inhibitoren |
EP1401429A2 (en) | 2001-06-29 | 2004-03-31 | AB Science | Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
JP2004530730A (ja) | 2001-06-29 | 2004-10-07 | アブ サイエンス | 腫瘍の血管新生を治療するための強力で選択的かつ非毒性のc−kit阻害剤の使用法 |
JP2005502614A (ja) | 2001-06-29 | 2005-01-27 | アブ サイエンス | 多発性硬化症(ms)を治療するためのチロシンキナーゼ阻害剤の使用方法 |
JP2004536097A (ja) | 2001-06-29 | 2004-12-02 | アブ サイエンス | 自己免疫疾患を治療するためのチロシンキナーゼ阻害剤の使用法 |
US7700610B2 (en) | 2001-06-29 | 2010-04-20 | Ab Science | Use of tyrosine kinase inhibitors for treating allergic diseases |
US7678805B2 (en) | 2001-06-29 | 2010-03-16 | Ab Science | Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD) |
EP1401411A2 (en) | 2001-06-29 | 2004-03-31 | AB Science | Use of tyrosine kinase inhibitors for treating bone loss |
JP2004537537A (ja) | 2001-06-29 | 2004-12-16 | アブ サイエンス | 炎症性疾患を治療するためのチロシンキナーゼ阻害剤の使用法 |
US20030091974A1 (en) | 2001-06-29 | 2003-05-15 | Alain Moussy | Method for screening compounds capable of depleting mast cells |
US20040242612A1 (en) | 2001-09-20 | 2004-12-02 | Alain Moussy | Use of tyrosine kinase inhibitors for promoting hair growth |
DE60225590T2 (de) | 2001-09-20 | 2008-09-25 | Ab Science | C-kithemmer zur behandlung von bakteriellen infektionen |
JP2005511596A (ja) | 2001-09-20 | 2005-04-28 | アブ サイエンス | ヒトの皮膚を白くし、且つメラノサイト機能不全関連疾病を治療するためのチロシンキナーゼ阻害剤の使用方法 |
WO2003072106A2 (en) | 2002-02-27 | 2003-09-04 | Ab Science | Use of tyrosine kinase inhibitors for treating substance use disorders |
WO2003072090A2 (en) | 2002-02-27 | 2003-09-04 | Ab Science | Use of tyrosine kinase inhibitors for treating cns disorders |
EP1507776B1 (en) * | 2002-05-29 | 2007-02-28 | Amgen Inc. | 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders |
ES2294344T3 (es) * | 2002-08-02 | 2008-04-01 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazoles y su utilizacion como inhibidores de c-kit. |
SE0202462D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel use |
WO2004072068A1 (en) * | 2003-02-10 | 2004-08-26 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
JP2006519220A (ja) | 2003-02-27 | 2006-08-24 | アブ サイエンス | 異なる型の肥満細胞症に適合可能なテイラーメイド治療方法 |
FR2854158B1 (fr) * | 2003-04-25 | 2006-11-17 | Sanofi Synthelabo | Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique |
MXPA06001098A (es) * | 2003-07-29 | 2006-04-24 | Irm Llc | Compuestos y composiciones utiles como inhibidores de proteina cinasa. |
EP1653934B1 (en) | 2003-08-15 | 2008-05-14 | AB Science | Use of c-kit inhibitors for treating type ii diabetes |
US7363881B2 (en) | 2003-11-06 | 2008-04-29 | Nova-Tech Engineering, Inc. | Beak treatment with tongue protection |
CN101456841B (zh) | 2003-12-25 | 2012-01-25 | 日本新药株式会社 | 酰胺衍生物及医药品 |
US7650848B2 (en) * | 2004-02-17 | 2010-01-26 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
WO2005115385A1 (en) * | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating acne |
TW200702876A (en) * | 2005-07-04 | 2007-01-16 | Avermedia Tech Inc | Projector device capable of sychronously encoding audio and video to become AV sychronous paly file |
-
2008
- 2008-02-13 WO PCT/EP2008/051704 patent/WO2008098949A2/en active Application Filing
- 2008-02-13 PL PL08708929T patent/PL2118099T3/pl unknown
- 2008-02-13 SI SI200830399T patent/SI2118099T1/sl unknown
- 2008-02-13 TW TW097105021A patent/TWI406862B/zh active
- 2008-02-13 EP EP11170200.7A patent/EP2366703B1/en active Active
- 2008-02-13 CA CA2677586A patent/CA2677586C/en active Active
- 2008-02-13 CA CA2970628A patent/CA2970628C/en active Active
- 2008-02-13 EP EP08708929A patent/EP2118099B1/en active Active
- 2008-02-13 ES ES11170200.7T patent/ES2522169T3/es active Active
- 2008-02-13 CN CN2008800049044A patent/CN101657446B/zh active Active
- 2008-02-13 PL PL11170200T patent/PL2366703T3/pl unknown
- 2008-02-13 KR KR1020097016822A patent/KR20090110851A/ko not_active Application Discontinuation
- 2008-02-13 AU AU2008214679A patent/AU2008214679A1/en not_active Abandoned
- 2008-02-13 AT AT08708929T patent/ATE515506T1/de not_active IP Right Cessation
- 2008-02-13 JP JP2009549405A patent/JP5568312B2/ja active Active
- 2008-02-13 ES ES08708929T patent/ES2369617T3/es active Active
- 2008-02-13 AR ARP080100620A patent/AR065337A1/es active IP Right Grant
- 2008-02-13 US US12/526,827 patent/US8153792B2/en active Active
- 2008-02-13 NZ NZ578944A patent/NZ578944A/en unknown
- 2008-02-13 SI SI200831294T patent/SI2366703T1/sl unknown
- 2008-02-13 MX MX2009008665A patent/MX2009008665A/es active IP Right Grant
- 2008-02-13 RU RU2009132186/04A patent/RU2456285C2/ru active
- 2008-02-13 CN CN201310141370.2A patent/CN103342701B/zh active Active
- 2008-02-13 BR BRPI0807626-0A patent/BRPI0807626B1/pt active IP Right Grant
-
2009
- 2009-08-10 IL IL200320A patent/IL200320A0/en unknown
- 2009-08-11 MA MA32161A patent/MA31180B1/fr unknown
- 2009-08-11 TN TNP2009000342A patent/TN2009000342A1/fr unknown
- 2009-08-28 ZA ZA2009/05981A patent/ZA200905981B/en unknown
-
2011
- 2011-10-05 HR HR20110709T patent/HRP20110709T1/hr unknown
-
2012
- 2012-03-08 US US13/415,249 patent/US8492545B2/en active Active
- 2012-04-12 RU RU2012114234/04A patent/RU2491286C1/ru active
-
2013
- 2013-05-10 US US13/891,639 patent/US8940894B2/en active Active
- 2013-05-30 JP JP2013113789A patent/JP5784073B2/ja active Active
-
2014
- 2014-10-15 HR HRP20140986AT patent/HRP20140986T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20140986T1 (hr) | Polimorfni oblik derivata 2-amino(nitroaril)tiazola | |
CN101360706B (zh) | (r)-芳基烷基氨基衍生物及其药物组合物 | |
WO2009034308A3 (en) | Process for the preparation of a raf kinase inhibitor and intermediates for use in the process | |
NO20063942L (no) | Saltformer av 4(-4-metylpiperazin-1-ylmetyl)-n-[4-metyl-3-(4-piperidin-3-yl)pyrimidin-2-ylamino)fenyl]-benzamid | |
ES2634291T3 (es) | Sales de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida | |
UA84462C2 (ru) | Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой | |
HRP20130102T1 (hr) | Postupak dobivanja spojeva 4-amino-2-(2,6-dioksopiperidin-3-il)izoindolin-1,3-diona | |
BR112017005410B1 (pt) | Compostos de uracila contendo anel de isoxazolina e os usos dos mesmos | |
TR200701870T1 (tr) | İmatinib mesilatın kararlı kristal formu ve bu formun hazırlanması için işlem. | |
AR088043A1 (es) | Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato | |
JP2006513238A5 (hr) | ||
CA2614098A1 (en) | Thiazoles derivatives as ampk activator | |
JP2009533369A5 (hr) | ||
JP2009531465A5 (hr) | ||
JP2018505199A5 (hr) | ||
BRPI0718812A2 (pt) | Processo para a preparação de imatinib e intermediários deste | |
DK1963307T3 (da) | 3-(4-{[4-(4-{[3-(3,3-dimethyl-1-piperidinyl)propyl]oxy}phenyl)-1-piperidinyl]carbonyl}-1-naphthalenyl)propion- eller propensyre som H1- og H3-receptorantagonister til behandling af inflammatoriske og/eller allergiske lidelser | |
JPS6343390B2 (hr) | ||
WO2008089436A3 (en) | Crystalline forms of histone deacetylase inhibitors | |
CN105523999B (zh) | 一种达比加群酯中间体的合成方法 | |
WO2006133904A3 (en) | Methods and intermediates for the preparation of optionally radio-labeled imatinib | |
RU2010141996A (ru) | Ингибитор ммр-2 и/или ммр-9 | |
CN110804034A (zh) | 精呋霜灵的合成方法 | |
RU2331638C2 (ru) | 2-тиозамещенные производные имидазола и их применение в фармацевтике | |
EA201791402A1 (ru) | 3-(6-АЛКОКСИ-5-ХЛОРБЕНЗО[d]ИЗОКСАЗОЛ-3-ИЛ) ПРОПИОНОВАЯ КИСЛОТА, ПОЛЕЗНАЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНУРЕНИНМОНООКСИГЕНАЗЫ |